Welcome to our dedicated page for Kyowa Hakko news (Ticker: KYKOY), a resource for investors and traders seeking the latest updates and insights on Kyowa Hakko stock.
Kyowa Kirin Co., Ltd. (KYKOY) is a global specialty pharmaceutical leader focused on innovative therapies for oncology, immunology, and rare diseases. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access official press releases and curated analysis covering clinical trial results, manufacturing expansions, and research collaborations. Our repository tracks progress across Kyowa Kirin's antibody therapeutics pipeline and global market activities.
Key updates include consolidated reporting on FDA/EMA regulatory filings, financial earnings, and partnership announcements. Bookmark this page for efficient monitoring of therapeutic advancements and corporate developments impacting the biopharmaceutical sector.
Kyowa Kirin has appointed Steve Schaefer as the new President of North America, effective April 11, 2023. Schaefer joins from Takeda where he held senior roles, including Senior Vice President of the Neuroscience Business Unit. With over 25 years of experience in the pharmaceutical sector, he has been integral in managing multi-billion dollar commercial portfolios and is known for his expertise in advanced analytics and sales operations.
Schaefer succeeds Gary Zieziula, who is retiring after leading the company through significant growth since April 2020. Under Zieziula's leadership, Kyowa Kirin North America has become the fastest-growing region for the company, contributing over a quarter of global revenues. The transition aims to further enhance Kyowa Kirin's innovative therapies across North America.
Kyowa Kirin Co., Ltd. announces the presentation of Phase 2b study data for rocatinlimab (KHK4083/AMG 451) at the American Academy of Dermatology 2023 Annual Meeting from March 17-22 in New Orleans. The trial involved 274 patients with moderate-to-severe atopic dermatitis, demonstrating significant reductions in serum IgE concentrations and improvements in patient-reported outcomes. Rocatinlimab's IgE reductions were maintained to Week 56. The study's adverse events were similar across groups, with no serious complications reported. Collaborative efforts with Amgen are also highlighted to further develop this potential treatment.
Kyowa Kirin Co., Ltd. announced the presentation of data from its Phase 2b study of rocatinlimab at the American Academy of Dermatology 2023 Annual Meeting on March 17-21 in New Orleans. Rocatinlimab, an investigational anti-OX40 monoclonal antibody, aims to treat moderate-to-severe atopic dermatitis, which affects approximately 15-20% of children and 10% of adults globally. Two posters will be presented, focusing on its efficacy and the reduction of IgE concentrations. Kyowa Kirin has partnered with Amgen for the development and commercialization of rocatinlimab globally, except in Japan, where it retains rights.
FAQ
What is the current stock price of Kyowa Hakko (KYKOY)?
What is the market cap of Kyowa Hakko (KYKOY)?
